

Title	A semi-supervised tensor regression model for siRNA efficacy prediction
Author(s)	Thang, Bui Ngoc; Ho, Bao Tu; Kanda, Tatsuo
Citation	BMC Bioinformatics, 16: 80
Issue Date	2015-03-13
Type	Journal Article
Text version	publisher
URL	http://hdl.handle.net/10119/15263
Rights	Thang et al. BMC Bioinformatics (2015) 16:80, DOI : 10.1186/s12859-015-0495-2 © 2015 Thang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Description	

METHODOLOGY ARTICLE

Open Access

A semi-supervised tensor regression model for siRNA efficacy prediction

Bui Ngoc Thang^{1,2*†}, Tu Bao Ho^{1,3†} and Tatsuo Kanda^{4†}

Abstract

Background: Short interfering RNAs (siRNAs) can knockdown target genes and thus have an immense impact on biology and pharmacy research. The key question of which siRNAs have high knockdown ability in siRNA research remains challenging as current known results are still far from expectation.

Results: This work aims to develop a generic framework to enhance siRNA knockdown efficacy prediction. The key idea is first to enrich siRNA sequences by incorporating them with rules found for designing effective siRNAs and representing them as enriched matrices, then to employ the bilinear tensor regression to predict knockdown efficacy of those matrices. Experiments show that the proposed method achieves better results than existing models in most cases.

Conclusions: Our model not only provides a suitable siRNA representation but also can predict siRNA efficacy more accurate and stable than most of state-of-the-art models. Source codes are freely available on the web at: <http://www.jaist.ac.jp/~bao/BILTR/>.

Keywords: RNAi, siRNA, siRNA design rule, Tensor, Bilinear tensor regression, Semi-supervised learning

Background

RNA interference (RNAi) is a cellular process in which RNA molecules inhibit gene expressions, typically by causing the destruction of mRNA molecules. Long double stranded RNA duplex or hairpin precursors are cleaved into short interfering RNAs (siRNAs) by the ribonuclease III enzyme Dicer. The siRNAs are sequences of 19–23 nucleotides (nt) in length with 2 nt overhangs at the 3' ends. Guided by RNA induced silencing complex (RISC), siRNAs bind to their complementary target mRNAs and induce their degradation.

In 2006, Fire and Mello received the Nobel Prize for their contributions to research on RNA interference (RNAi). Their work and those of others on discovery of RNAi have had an immense impact on biomedical research and will most likely lead to novel medical applications [1–6]. In RNAi research, highly effective siRNAs can

be synthesized to design novel drugs for viral-mediated diseases such as influenza A virus, HIV, hepatitis B virus, RSV viruses, cancer disease and so on. As a result, siRNA silencing is considered one of the most promising techniques in future therapy and predicting their inhibition efficiency is crucial for proper siRNA selection. Therefore finding the most effective siRNAs constitutes a huge challenge facing researchers [7–14]. Numerous algorithms have been developed to design and predict effective siRNAs. These algorithms could be divided into two following generations [15–17].

The first generation consists of siRNA design rule-based tools that were developed through the analysis of small datasets. Various siRNA design rules have been found by empirical processes since 1998. The first rational siRNA design rule was detected by Elbashir *et al.* [18]. They suggested that siRNAs having 19–21 nt in length with 2 nt overhangs at the 3' ends can efficiently silence mRNAs. Scherer *et al.* [19] reported that the thermodynamic properties to target specific mRNAs are important characteristics. Soon after these studies, many rational design rules for effective siRNAs have been proposed [20–26]. For example, Reynolds *et al.* [22] analyzed 180

*Correspondence: thangbn@jaist.ac.jp

†Equal contributors

¹School of Knowledge Science, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, Ishikawa, Japan

²University of Engineering and Technology, Vietnam National University Hanoi, 144 Xuan Thuy, Cau Giay, Hanoi, Vietnam

Full list of author information is available at the end of the article

siRNAs systematically, targeting every other position of two 197–base regions of luciferase and human cyclophilin B mRNA (90 siRNAs per gene), and found the following eight criteria for improving siRNA selection: (i) G/C content 30–52%, (ii) at least 3 As or Us at positions 15–19, (iii) absence of internal repeats, (iv) an A at position 19, (v) an A at position 3, (vi) an U at position 10, (vii) a base other than G or C at position 19, (viii) a base other than G at position 13.

However, the performance of tools in the first generation was not high enough to our satisfaction. About 65% of siRNAs produced by the above-mentioned design rules have failed when experimentally tested, says, they were 90% in inhibition and nearly 20% of them were found to be inactive [27]. One reason is that the previous empirical analyses were only based on small datasets and focused on siRNAs for specific genes. Therefore, each of these rules is poor to individually design highly effective siRNAs.

The second generation consists of predictive models by employing machine learning techniques that were learned through larger datasets. Tools based on these models in this generation are more accurate and reliable than tools in the first one [28]. In particular, Huesken and colleagues [29] developed a new algorithm, Biopredsi, by applying artificial neural networks to a dataset consisting of 2431 scored siRNAs (i.e., siRNAs whose knockdown efficacy (score) was experimentally observed). This dataset was widely used to train and test other predictive models such as the ThermoComposition21 [28], DSIR [7], i-Score [15] and Scales models [30]. The five above mentioned models are currently estimated as the best predictors [16,30]. Most notably, Qui *et al.* [31] used multiple support vector regression with RNA string kernel for siRNA efficacy prediction, and Sciabola *et al.* [17] applied three-dimension structural information of siRNA to increase predictability of their regression model. Alternatively, several works [32,33] used classification methods on labeled siRNAs which were experimentally labeled in terms of knockdown efficacy.

It is worth noting that most of those methods suffer from some drawbacks. Their performance is still slow and unstable. It can be caused by the following reasons: (i) siRNAs datasets are heterogeneous provided by different groups under different protocols in different scenarios [33,34]. Thus the performance of these models is considerably decreased and changed when they were tested on independent datasets such as the performance of 18 current models tested on three independent datasets [17]. (ii) The performance of machine learning methods also heavily depends on the choice of data representation (or features) on which they are applied. In the previous models, siRNAs were encoded by binary, spectral, tetrahedron, and sequence representations. However, because of siRNA distribution diversity and unsuitable measures

based on these siRNA representations, they can be inappropriate to represent siRNAs in order to build a good model for predicting siRNA efficacy.

Our work aims to develop a higher and more stable model to predict the siRNA knockdown efficacy. To this end, we focus on two main tasks: constructing an appropriate representation of siRNA and building a predictive model. In the first task, in order to enrich the representation of siRNAs, available siRNA design rules in the first generation that are considered as prior background knowledge are alternately incorporated to transformation matrices. In the learning process of these transformation matrices, labeled siRNAs collected from heterogeneous courses are used to capture properties of the proposed representation: the natural clustering property of each class and the distribution diversity of siRNAs. A scored siRNA dataset is also employed to ensure that the representation satisfies the smoothness of our predictive model. In the second task, transformation matrices are weighted and used to transform each siRNA to the enriched matrix representation. A bilinear tensor regression model is developed and learned to predict siRNA knockdown efficacy. To improve the accuracy of the proposed model, the labeled siRNAs are also used in addition to the scored dataset to supervise the learning process of parameters. To obtain more precise data representation, the transformation matrices and parameters are iteratively and simultaneously learned. In the objective function, the Frobenius norm is appropriately replaced by L_2 regularization norm for an effective computation. The contributions of this work are summarized as follows

1. Construct a suitable representation of siRNAs, enriched matrix representation, by incorporating available siRNA design rules and employing both of labeled and scored siRNAs.
2. Develop a higher and stable predictive method to predict the siRNA efficacy by building the bilinear tensor regression model. The learning processes of transformation matrices and parameters of the model are combined together to make more accurate and precise siRNA representation. Labeled siRNAs are used to supervise the learning process of parameters.
3. Quantitatively determine positions on siRNAs where nucleotides can strongly influence inhibition ability of siRNAs.
4. Provide guidelines based on positional features for generating highly effective siRNAs.

We developed a bilinear tensor regression predictor, BiLTR, by using C++ programming language on X-Code environment. BiLTR is experimentally compared with published models on the Huesken dataset and three independent datasets commonly used by the research

community. The results show that the performance of the BiLTR predictor is more stable and higher than that of other models.

Results

This section presents experimental evaluation by comparing the proposed method of bilinear tensor regression model (BiLTR) with the most recent reported methods for siRNA knockdown efficacy prediction on commonly datasets.

The experiments are carried out using four scored datasets

- The Huesken dataset of 2431 siRNA sequences targeting 34 human and rodent mRNAs, commonly divided into the training set HU_train of 2182 siRNAs and the testing set HU_test of 249 siRNAs [29].
- The Reynolds dataset of 240 siRNAs [22].
- The Vicker dataset of 76 siRNA sequences targeting two genes [35].
- The Harborth dataset of 44 siRNA sequences targeting one gene [36].

To construct siRNA representation and learn BiLTR model, we employed labeled and scored siRNA datasets as well as seven siRNA design rules. The seven design rules used to enrich representation of siRNAs are Reynolds rule, Uitei rule, Amarzguioui rule, Jalag rule, Hsieh rule, Takasaki rule and Huesken rule [20-23,29,37,38]. To capture the natural clustering and the diversity properties of siRNAs, and also supervise the parameter learning process, the labeled siRNAs were collected from the siRecords database [27] consisting of siRNAs classified into 4 classes: ‘very high’, ‘high’, ‘medium’, and ‘low’ knockdown efficacy. This database is an extensive one of mammalian RNAi experiments with consistent efficacy ratings. siRecords consists of the records of all kinds of siRNA experiments conducted with various laboratory techniques and experimental settings. In our work, sense siRNAs of 19 nucleotides in length were collected. After removing duplicative siRNAs, ‘very high’ and ‘medium’ and ‘low’ siRNAs were used (to improve the balance between classes while keeping the separation between them, ‘medium’ and ‘low’ siRNAs were merged into one class, denoted by ‘low’). As a result, there are 2470 labeled siRNAs in the ‘very high’ class and 2514 labeled siRNAs in the ‘low’ class. Scored siRNAs in the Huesken dataset were also used to learn BiLTR model.

Transformation matrices T_k ($k = 1, \dots, K$), coefficient vectors α and β are learned by employing Algorithm 1. In this algorithm, the convergence criteria were set as follows: the thresholds ϵ , ϵ_1 and ϵ_2 were set by small numbers, actually 0.001. The maximum iterative step, t_{Max} , was 2000. Moreover, one crucial issue is to find turning

parameters of objective function 10. In our work, the turning parameters of the objective function λ_1 , λ_2 and λ_3 were estimated by minimizing a risk function of the proposed model when the model is tested on validation sets. Particularly, besides using the labeled siRNAs and siRNA design rules, we implement 10-fold cross validation on a scored siRNA training set for each turning parameter belonging to the interval $[0, \log(10)]$. The model is trained for each triple of $(\lambda_1, \lambda_2, \lambda_3)$. After that, we compute the following risk function

$$R(\lambda_1, \lambda_2, \lambda_3) = \frac{1}{F} \sum_{i=1}^F \frac{1}{\|fold_i\|} L(T_1, \dots, T_K, \alpha, \beta) \quad (1)$$

where $fold_i$ is the validation set, F is the number of folds to do cross validation on the training set. $L(T_1, \dots, T_K, \alpha, \beta)$ is the objective function mentioned in the Methods section. We employ 10-fold cross validation, and thus F equals to 10. Concerning the stability of learning turning parameters, 10 times of 10-fold cross validation are implemented. As a result, the fitted turning parameters of each run of 10-fold cross validation are shown in Table 1. Standard deviations of the parameters λ_1 , λ_2 and λ_3 are 0.004, 0.00003, and 0.035, respectively so learned turning parameters are more stable. The triple of turning parameters that the value of the risk function is minimum are employed to learn the final model.

After finding turning parameters, the final model, BiLTR, is learned by using all of the labeled siRNAs, the siRNA design rules, and the scored siRNA training set.

The BiLTR model is compared to most of state-of-the-art methods for siRNA knockdown efficacy prediction recently reported in the literature. For a fair comparison, we carried out experiments on BiLTR in the same conditions as they did and then compared our obtained results with the ones published in their reports. Concerning training dataset, besides all of models were trained

Table 1 The fitted turning parameters of objective function 10 in 10 times of 10-fold cross validation

λ_1	λ_2	λ_3
0.00995033	0.000119984	1.03
0.00995033	0.000119984	1.02
0.00995033	0.000119993	1.03
0.00995033	0.000119993	1.03
0.0198026	0.000119993	1.03
0.0198026	9.9995e-05	1.03
0.00995033	0.00013999	1.03
0.00995033	0.000179984	1.03
0.00995033	0.000179984	1.03
0.00995033	0.000179984	0.92

on the same scored siRNA dataset, we also used siRNA design rules and a labeled siRNA dataset to train the BiLTR model. Concretely, the comparative evaluation is as follows

1. Comparison of BiLTR with Multiple Kernel Support Vector Machine proposed by [31]. The authors reported their Pearson correlation coefficient (R) of 0.62 obtained by 10-fold cross validation on the whole Huesken dataset. The Pearson correlation coefficient (R) is carefully evaluated by BiLTR by 10 times of 10-fold cross validation with the average value of 0.64 (Table 2). Concerning the standard deviation (SD) of error rates between predicted and target labels, the SD of our model is 0.23, however Qui and co-workers [31] did not show.
2. Comparison of BiLTR with BIOPREDSi [29], Thermocomposition21 [28], DSIR [7], and SVM [17] when trained on the same scored siRNA dataset, HU_train and tested on the HU_test dataset. The R values of those four models are 0.66, 0.66, 0.67 and 0.80, respectively. The SD values of the first three models are 0.216, 0.216, and 0.161, respectively. However, SD value of the SVM model was not shown. The R value of BiLTR estimated on the HU_test set is 0.67 that is equivalent to the R value of DSIR model, slightly higher than that of the first two models but lower than that of the last model (Table 2). The SD value of the BiLTR model is 0.164 that is similar to the SD value of the DSIR model and higher than that of first two models as well. It can be observed that the performance of SVM is significantly better than that of BiLTR in Table 2. One reason comes from the current limitation of BiLTR as it employs positional features of available design rules but not other characteristics such as GC content, thermodynamic properties, GC stretch, and 3D information while SVM employs positional features and 3D information. This feature captures the flexibility and strain of siRNAs that can be

Table 2 The R values and standard deviations of models on the the whole Huesken dataset and HU_test dataset

Algorithm	Huesken dataset (2431 siRNAs)	HU_test (249 siRNAs)
Qui's method	0.62 (-)	-
BIOPREDSi	-	0.66 (0.216)
Thermocomposition21	-	0.66 (0.216)
DSIR	-	0.67 (0.161)
SVM	-	0.80 (-)
BiLTR	0.64 (0.23)	0.67 (0.164)

The Person correlation coefficients R and standard deviations SD are formed by R (SD).

important characteristics for siRNAs of the HU_test set extracted from human NCI-H1299, Hela genes and rodent genes [29]. Therefore, at this moment the performance of the BiLTR model is similar to that of BIOPREDSi, Thermocomposition21, DISR models but cannot achieve higher performance than the SVM model [17] when tested on the HU_test set.

3. Comparison of BiLTR with 18 models including BIOPREDSi, DSIR, SVM when all of models were trained on the HU_train set and tested on three independent datasets of Reynolds, Vicker and Harborth as reported in the recent article [17]. We also computed SD values of error rates between predicted and experimental variables. However, we lack of standard deviations of some models, especially that of the SVM model, because their models' predicted labels were not shown in their publication. As a result, the BiLTR considerably achieved results higher than all of 18 methods on the all three independent testing datasets as shown in Table 3 (taken from [17] with the last row added for the BiLTR result). The lower performance of SVM than BiLTR in Table 1 can be explained as the added 3D information in SVM does not make it better than

Table 3 The R values and standard deviations of 18 models and BiLTR on three independent datasets

Algorithm	$R^{Reynolds}$ (244si/7 g)	R^{Vicker} (76si/2 g)	$R^{Harborth}$ (44si/1 g)
GPboot [39]	0.55 (-)	0.35 (-)	0.43 (-)
Uitei [23]	0.47 (-)	0.58 (-)	0.31 (-)
Amarzguoui [20]	0.45 (0.30)	0.47 (0.23)	0.34 (0.12)
Hsieh [37]	0.03 (0.31)	0.15 (0.23)	0.17 (0.12)
Takasaki [40]	0.03 (0.3)	0.25 (0.23)	0.01 (0.14)
Reynolds 1 [22]	0.35 (0.3)	0.47 (0.224)	0.23 (0.12)
Reynolds 2 [22]	0.37 (0.291)	0.44 (0.232)	0.23 (0.12)
Schwarz [24]	0.29 (-)	0.35 (-)	0.01 (-)
Khvorova [41]	0.15 (-)	0.19 (-)	0.11 (-)
Stockholm 1 [42]	0.05 (-)	0.18 (-)	0.28 (-)
Stockholm 2 [42]	0.00 (-)	0.15 (-)	0.41 (-)
Tree [42]	0.11 (-)	0.43 (-)	0.06 (-)
Luo [43]	0.33 (-)	0.27 (-)	0.40 (-)
i-score[15]	0.54 (0.262)	0.58 (0.19)	0.43 (0.12)
BIOPREDSi [29]	0.53 (0.31)	0.57 (0.23)	0.51 (0.12)
DSIR [7]	0.54 (0.26)	0.49 (0.21)	0.51 (0.11)
Katoh [44]	0.40 (0.34)	0.43 (0.23)	0.44 (0.15)
SVM [17]	0.54 (-)	0.52 (-)	0.54 (-)
BiLTR	0.57 (0.25)	0.58 (0.19)	0.57 (0.10)

The Person correlation coefficients R and standard deviations SD are formed by R (SD).

BiLTR, especially when testing data are more independent from the Huesken dataset. The lower performance of SVM than BiLTR in Table 3 can be viewed as the added 3D information in SVM does not always make it better than BiLTR, especially when testing data are more independent from the Huesken dataset. Besides that, unlike most of other models, the BiLTR model produces the stable results across each of independent siRNA datasets.


In these comparative studies, it was found that the performance of BiLTR is more stable and higher than that of other models. The first reason is that previous siRNA representations can be unsuitable to represent siRNAs provided different groups under different protocols. In our method, the representation is enriched by incorporating background knowledge of siRNA design rules and learned by employing heterogeneous labeled siRNAs. By combining the representation and parameter learning processes together. Therefore it can capture the distribution diversity of siRNA data. The second reason is that using labeled siRNAs in different distributions to learn our model, BiLTR model can predict more accurate knockdown efficacy of siRNAs.

Discussion

In this section, we discuss more detail about three main issues: the performance of BiLTR model, the importance of learned transformation matrices and the effect of nucleotide design at particular positions on siRNAs.

Concerning the first issue, as presented in the experimental comparative evaluation, BiLTR achieved better results than most other methods in predicting siRNA knockdown efficacy. There are some reasons for that. First, it is expensive to experimentally analyze the knockdown efficacy of siRNAs, and thus most of available datasets have relatively small size leading to limited results. Second, BiLTR has its advantages by incorporating domain knowledge (siRNA design rules) experimentally found from different datasets. Third, BiLTR is generic and can be easily exploited when new design rules are discovered, or more scored or labeled siRNAs are obtained. As a result, when tested on the three independent datasets generated by different empirical experiments, the performance of BiLTR is better than that of the four above models. Additionally, some models achieve the best results as the BiLTR model when tested on the Vicker dataset (e.g., i-score, Uitei models) but none of them simultaneously reaches the highest result as BiLTR when tested on the three independent datasets (Table 3).

On the other hand, it is easy to see that the weights $\alpha_i, i = 1, \dots, K$ show the importance of the siRNA design rules that affect the knockdown efficacy of siRNAs. Figure 1 shows the weights of the seven siRNA



design rules. The second and the fourth siRNA ones corresponding to the Uitei and Jagla rules have the smallest and highest weights, respectively. The Uitei rule shows that nucleotides ‘G/C’ at position 1 and ‘A/U’ at position 19 correlate to effective siRNAs and nucleotides ‘A/U’ at position 1 and ‘G/C’ at position 19 correlate to ineffective siRNAs. These characteristics are consistent with most of the other siRNA design rules. However, these characteristics based on positions 1 and 19 are insufficient to generate effective siRNAs. In the fourth rule, except characteristics of the Uitei rule, Jagla and colleagues discovered that effective siRNA have an ‘A/U’ nucleotide at position 10. It also shows the importance of these nucleotides at position 10 when designing effective siRNAs.

Concerning the second issue, the learned transformation matrices not only capture the characteristics of the siRNA design rules but also guide to create new design rules for generating effective siRNA candidates. Table 4 shows the positional features of the Reynolds rule. In this siRNA design rule, effective siRNAs satisfy the following criteria on sense siRNA strands: (i) nucleotide ‘A’ at position 3; (ii) nucleotide ‘U’ at position 10; (iii) nucleotides ‘A/C/U’ at position 13 and (iv) nucleotides ‘A/U’ at position 19. After learning BiLTR, the transformation matrix capturing positional features of the Reynolds rule is determined. Figure 2 shows the learned transformation matrix incorporated with the Reynolds rule. In this figure, each column of the matrix is normalized to easily observe. One of the characteristics is described as “an nucleotide ‘A/U’ at position 19”. This characteristic means that at column 19, the cell (4,19) should contain the maximum value. In the matrix, the value at this cell is 0.86009595 and is the greatest value in this column. We now consider other characteristics of the Reynolds rule. Another

Table 4 Characteristics of Reynolds rule

Position	3	10	13	19
Effective	A	U	A/C/G	A/U




Figure 2 The learned transformation matrix incorporating positional features of the Reynolds rule. Histogram shows knockdown efficacy strength of each nucleotide at positions on sense siRNA strand.

characteristic of this rule is that effective siRNAs have at least three nucleotides ‘A/U’ at positions from 15 to 19. In learned transformation matrix, corresponding values of nucleotides ‘A/U’ at positions 15, 18 and 19 are the greatest ones (see Figure 2). Therefore, the transformation matrix can preserve this characteristic of the Reynolds rule. One characteristic of siRNAs such as ‘G/C’ content ranging from 30% to 52% is also preserved in the learned transformation matrix. In addition, positions on siRNAs are not described in characteristics of the design rules, the knockdown efficacy of nucleotides at columns corresponding to these positions are also learned to satisfy the classification assumption and constraints of BiLTR as values at columns 1, 2, 4 and so on. Therefore, after learning the transformation matrices based on the siRNA design rules, these transformation matrices can guide to generate effective siRNAs. For example, Figure 2 shows the Reynolds rule based transformation matrix and its histogram of nucleotides at positions on sense siRNA strand. We can see that effective siRNAs can be designed by using the Reynolds rule and other characteristics such as: ‘U’ at position 12, ‘A’ at position 13, and so on.

Concerning the last issue, we consider the effect of nucleotides at particular positions on siRNAs. In BiLTR model, coefficients β_j , $j = 1, \dots, 19$, show the strength of the relationship between each variable corresponding to each column of tensors representing siRNAs and the inhibition ability of siRNAs. We know that values of each column show the knockdown efficacy of each nucleotide in a siRNA sequence by incorporating the seven siRNA design rules. Therefore, the coefficients show the influence of nucleotide design at positions on siRNAs to the inhibition ability. In Figure 3, the coefficients at positions 4, 16 and 19 show that the siRNA design at these positions will strongly influence the knockdown efficacy or inhibition of siRNAs. Most of the siRNA design rules also capture the importance of designing nucleotides at positions 16 and 19 but they do not mention the designing of nucleotides at position 4. Therefore, the influence of nucleotides at this position can be considered to design effective siRNAs.

Conclusion

In this paper, we have proposed a novel method to predict the knockdown efficacy of siRNA sequences by using both labeled and scored datasets as well as available design rules to transform the siRNAs into enriched matrices, then learn a bilinear tensor regression model for the prediction purpose. Besides that, in the model an appropriate siRNA representation is also developed to represent siRNAs belonging to different distributions that are provided by research groups under different protocols.

The experimental comparative evaluation on commonly used datasets with standard evaluation procedure in different contexts shows that the proposed method achieved better results than most existing methods in doing the same task. One significant feature of the proposed method is it can easily be extended when new design rules are discovered as well as more siRNAs are analyzed by empirical processes. By analyzing BiLTR model, we provide guidelines to generate effective siRNAs, and detect positions on siRNAs where nucleotides can strongly effect the inhibition ability.

Methods

We formulate the problem of siRNA knockdown efficacy prediction as follows




Figure 3 Coefficients of 19 dimensions corresponding to 19 position on siRNAs.

- **Given:** Two sets of labeled and scored siRNAs of length n , and a set of K siRNA design rules.
- **Find:** A function that predicts the knockdown efficacy of given siRNAs.

Our proposed method consists of three major steps that are described in Table 5.

Step 1 of the method is done where each siRNA sequence with n nucleotides in length is encoded as a binary encoding matrix of size $n \times 4$. In fact, four nucleotides A, C, G, or U are encoded by encoding vectors (1, 0, 0, 0), (0, 1, 0, 0), (0, 0, 1, 0) and (0, 0, 0, 1), respectively. If a nucleotide from A, C, G, and U appears at the j th position in a siRNA sequence, $j = 1, \dots, n$, its encoding vector will be used to encode the j th row of the encoding matrix.

Step 2 is to transform the encoding matrices by transformation matrices T_k regarding the k th design rule, $k = 1, \dots, K$. T_k has size of $4 \times n$ where the rows correspond to nucleotides A, C, G, and U, and the columns correspond to n positions on sequences. T_k are learned from the k th design rule. Each cell $T_k[i, j]$, $i = 1, \dots, 4$, $j = 1, \dots, n$, represents the knockdown ability of nucleotide i at position j regarding the k th design rule. Each transformation matrix has to satisfy types of following constraints. The first type of constraints is basic constraints on elements of T_k

$$T_k[i, j] \geq 0, i = 1, \dots, 4; j = 1, 2, \dots, n \tag{2}$$

The second type of constraints is generated to incorporate background knowledge of the k th siRNA design rule to the transformation matrix T_k ($k = 1, \dots, K$). As above mentioned, $T_k[1, j]$, $T_k[2, j]$, $T_k[3, j]$, and $T_k[4, j]$ show knockdown efficacy of nucleotides A, C, G and U at position j th ($j = 1, \dots, n$), respectively. Furthermore, the k th design rule describes the design of effective siRNAs that consists of the effectiveness or ineffectiveness of nucleotides at some positions of siRNAs. Therefore,

Table 5 Method for siRNA knockdown efficacy prediction

1	To encode each siRNA sequence as an encoding matrix X representing the nucleotides A, C, G, and U at n positions in the sequence. Thus, siRNAs are represented as $n \times 4$ encoding matrices.
2	To transform encoding matrices by K transformation matrices T_k into enriched matrices, $k = 1, \dots, K$. Each transformation matrix characterizes the knockdown ability of nucleotides A, C, G, and U at n positions in the siRNA sequence regarding the k th design rule. Each T_k captures background knowledge of the k th design rule. The enriched matrices of size $K \times n$ are considered as second order tensors of the siRNA sequences.
3	To build and learn a bilinear tensor regression model. In this step, K transformation matrices as well as parameters of the model are learned together with the labeled and scored siRNAs and available siRNA design rules. The final model is used to predict the efficacy of new siRNAs.

trick inequality constraints on the transformation matrix T_k are as follows: in the siRNA design rule k th, if some nucleotides at position j th are effective, their corresponding values are greater than the other values at column j th of T_k . In contrast, if some nucleotides are ineffective, their corresponding values are smaller than the other values at column j th of T_k . For example, the design rule in the right table in Table 6 illustrates that at position 19, nucleotides A/U are effective and nucleotide C is ineffective. It means that the knockdown efficacy of nucleotides A/U are larger than that of nucleotides G/C and knockdown efficacy of nucleotide C is smaller than that of the other nucleotides. Thus, values $T[1, 19]$, $T[2, 19]$, $T[3, 19]$ and $T[4, 19]$ show the knockdown efficacy of nucleotides A, C, G and U at position 19, respectively. Therefore, five trick inequality constraints at column 19 of T are formed. Generally, we denote the set of M_k trick inequality constraints on T_k by siRNA design rule k th under consideration by

$$\{g_m(T_k) < 0\}_{m=1}^{M_k} \tag{3}$$

where $g_m(T_k) < 0$ is a trick inequality constraint on transformation matrix T_k that is generated by siRNA design rule k th.

Let vector $x_l^{(k)}$ of size $1 \times n$ denote the transformed vector of the l th siRNA sequence using the transformation matrix T_k . The j th element of x_l is the element of T_k at column j and the row corresponds to the j th nucleotide in the siRNA sequence. To compute $x_l^{(k)}$, a new column-wise inner product is defined as follows

$$x_l^{(k)} = T_k \circ X_l = (X_l[1, \cdot] T_k[\cdot, 1], X_l[2, \cdot] T_k[\cdot, 2], \dots, X_l[n, \cdot] T_k[\cdot, n]) \tag{4}$$

where $X_l[j, \cdot]$ and $T[\cdot, j]$ are the j th row vector and the j th column of the matrix X_l and T , respectively, and xy is the inner product of vectors x and y .

Table 7 shows an example of encoding matrix X , transformation matrix T and transformed vector x of the given

Table 6 An example of incorporating the condition of a design rule at position 19 to a transformation matrix T by designing constraints

Position	Knockdown ability	Nucleotide	Mapping to T	Constraints on T
19	Effective	A, U	$T[1, 19]$,	$T[3, 19] - T[1, 19] < 0$
			$T[4, 19]$	$T[3, 19] - T[4, 19] < 0$
19	Ineffective	C	$T[2, 19]$	$T[2, 19] - T[1, 19] < 0$
				$T[2, 19] - T[3, 19] < 0$
				$T[2, 19] - T[4, 19] < 0$

Table 7 An example of encoding matrix, transformation matrix, and transformed vector (the values 0.5, 0.1 etc. are taken to the vector)

Sequence	Encoding matrix X	Transformation matrix T	Transformed data vector $x = T \circ X$
AUGCU	1 0 0 0	0.5 0.7 0.32 0.2 0.5	(0.5, 0.1, 0.08, 0.6, 0.1)
	0 0 0 1	0.3 0.1 0.6 0.6 0.3	
	0 0 1 0	0.1 0.1 0.08 0.1 0.1	
	0 1 0 0	0.1 0.1 0 0.1 0.1	
	0 0 0 1		

sequence AUGCU. The rows of X represent encoding vectors of nucleotides in the sequence. Given transformation matrix T of size 4×5 . The sequence AUGCU is represented by the vector $x = (T[1, 1], T[4, 1], T[3, 3], T[2, 4], T[4, 5]) = (0.5, 0.1, 0.08, 0.6, 0.1)$. Therefore, the transformed data can be computed by the column-wise inner product $x = T \circ X_l$.

The third type of constraints relates to preservation of natural clustering properties of each class after being transformed by using transformation matrices T_k . It means that siRNAs belonging to the same class should be more similar to each other than siRNAs belonging to the other class. This constraint is formulated as the following minimization problem

$$\min \sum_{\substack{p \in N_1 \\ q \in N_1}} d^2(x_p^{(k)}, x_q^{(k)}) + \sum_{\substack{p \in N_2 \\ q \in N_2}} d^2(x_p^{(k)}, x_q^{(k)}) - \sum_{\substack{p \in N_1 \\ q \in N_2}} d^2(x_p^{(k)}, x_q^{(k)}) \quad (5)$$

In this objective function, the first two components are the sum of similarities of sequence pairs belonging to the same class and the last one is the sum of similarities of sequence pairs belonging to two different classes; $d(x, y)$ is the similarity measure between x and y (in this work we use Euclidean distance and L_2 norm); N_1 and N_2 are the two index sets of ‘very high’ and ‘low’ labeled siRNAs, respectively.

In step 3 of the method, each encoding matrix X_l is transformed to K representations $(x_l^{(1)}, x_l^{(2)}, \dots, x_l^{(K)})$ or $(T_1 \circ X_l, T_2 \circ X_l, \dots, T_K \circ X_l)$ by K transformation matrices. Denote $R(X_l) = (T_1 \circ X_l, T_2 \circ X_l, \dots, T_K \circ X_l)^T$ be the second order tensor of size $K \times n$. The bilinear tensor regression model can be defined as follows

$$f(x) = \alpha R(X_l) \beta \quad (6)$$

where $\alpha = (\alpha_1, \alpha_2, \dots, \alpha_K)$ is a weight vector of the K representations of X_l and $\beta = (\beta_1, \beta_2, \dots, \beta_n)^T$ is a parameter vector of the model, and $\alpha R(X_l)$ component is the linear combination of representations $T_1 \circ X_l, T_2 \circ X_l, \dots, T_K \circ X_l$. It also shows the relationship among elements on each column of the second order tensor or each dimension of $T_k \circ X_l, k = 1, 2, \dots, K$. Equation (6) can be derived as follows

$$\begin{aligned} f(X_l) &= \alpha R(X_l) \beta = (\beta \otimes \alpha^T)^T \text{vec}(R(X_l)) \\ &= (\beta^T \otimes \alpha) \text{vec}(R(X_l)) \end{aligned}$$

where $A \otimes B$ is the Kronecker product of two matrices A and B , and $\text{vec}(A)$ is the vectorization of matrix A .

The fourth type of constraints related to the smoothness and the supervised learning phase of the model by employing labeled siRNAs. An appropriate representation and an accurate model have to satisfy that the knockdown efficacy of each siRNA sequence in the ‘very high’ class has to greater than that of siRNAs in the ‘low’ class. Therefore, let X_p denote the encoding matrix of the p th sequence in the ‘very high’ class and X_q denote the encoding matrix of the q th sequence in the ‘low’ class. We have the following constraints

$$\begin{aligned} (f(X_q) - f(X_p)) &\leq 0 \Leftrightarrow \alpha (R(X_q) - R(X_p)) \beta \\ &\leq 0 \quad p \in N_1, q \in N_2 \quad (7) \end{aligned}$$

We see that when labeled siRNAs are collected from heterogeneous courses, these constraints also preserve the stability of model when predicted siRNAs are generated by different protocols.

Therefore, the regularized risk function satisfies the constraints (7) is formulated as follows

$$\begin{aligned} L(\alpha, \beta) &= \sum_{l=1}^N (y_l - \alpha R(X_l) \beta)^2 + \lambda_1 \| \beta^T \otimes \alpha \|^2_{Fro} \\ &+ 2\lambda_2 \sum_{\substack{p \in N_1 \\ q \in N_2}} \alpha (R(X_q) - R(X_p)) \beta \quad (8) \end{aligned}$$

where λ_1, λ_2 are the turning parameters, and $\| \beta^T \otimes \alpha \|^2_{Fro}$ is the Frobenius norm of the first order tensor $\beta^T \otimes \alpha$. X_l and y_l are encoding matrix of the l th

sequence and its knockdown efficacy in the scored siRNA dataset, and N is the size of the scored siRNA sequences. The regularization term in equation (8) is derived as follows

$$\begin{aligned} \|\beta^T \otimes \alpha\|_{Fro}^2 &= \sum_{k=1}^K \sum_{j=1}^n (\alpha_k \beta_j)^2 = \sum_{k=1}^K \alpha_k^2 \sum_{j=1}^n \beta_j^2 \\ &= \sum_{k=1}^K \alpha_k^2 \|\beta\|_2^2 = \|\alpha\|_2^2 \|\beta\|_2^2 \end{aligned}$$

Therefore, equation (8) with the Frobenius norm can be replaced by L_2 norm

$$\begin{aligned} L(\alpha, \beta) &= \sum_{l=1}^N (y_l - \alpha R(X_l) \beta)^2 + \lambda_1 \|\alpha\|_2^2 \|\beta\|_2^2 \\ &\quad + 2\lambda_2 \sum_{\substack{p \in N_1 \\ q \in N_2}} \alpha(R(X_q) - R(X_p))\beta \end{aligned} \tag{9}$$

The problem has now become the following multi-objective optimization problem: Finding $\{T_k\}_1^K$, α and β to minimize objective function (10) under the constraints (2), (3) and minimize objective function (9). The multi-objective optimization problem is equivalent to the following optimization problem.

$$\begin{aligned} \min L(T_1, \dots, T_K, \alpha, \beta) &= \sum_{l=1}^N (y_l - \alpha R(X_l) \beta)^2 \\ &\quad + \lambda_1 \|\alpha\|_2^2 \|\beta\|_2^2 \\ &\quad + \lambda_2 \sum_{\substack{p \in N_1 \\ q \in N_2}} \alpha(R(X_q) - R(X_p))\beta \\ &\quad + \lambda_3 \sum_{k=1}^K \left(\sum_{p,q \in N_1} d^2(x_p^{(k)}, x_q^{(k)}) + \sum_{p,q \in N_2} d^2(x_p^{(k)}, x_q^{(k)}) \right. \\ &\quad \left. - \sum_{\substack{p \in N_1 \\ q \in N_2}} d^2(x_p^{(k)}, x_q^{(k)}) \right) \end{aligned}$$

Subject to $T_k[i, j] \geq 0$, $g_m(T_k) < 0$, $i = 1, \dots, 4$; $j = 1, \dots, n$; $k = 1, \dots, K$; $m = 1, \dots, M_k$.

This optimization problem is solved by the following Lagrangian form

$$\begin{aligned} L &= \sum_{l=1}^N (y_l - \alpha R(X_l) \beta)^2 + \lambda_1 \|\alpha\|_2^2 \|\beta\|_2^2 \\ &\quad + 2\lambda_2 \sum_{\substack{p \in N_1 \\ q \in N_2}} \alpha(R(X_q) - R(X_p))\beta + \sum_{k=1}^K \sum_{m=1}^{M_k} \mu_m^{(k)} g_m(T_k) \\ &\quad + \lambda_3 \sum_{k=1}^K \left(\sum_{p,q \in N_1} d^2(x_p^{(k)}, x_q^{(k)}) + \sum_{p,q \in N_2} d^2(x_p^{(k)}, x_q^{(k)}) \right. \\ &\quad \left. - \sum_{\substack{p \in N_1 \\ q \in N_2}} d^2(x_p^{(k)}, x_q^{(k)}) \right) \end{aligned} \tag{10}$$

where $\mu_m^{(k)}$, $m = 1, \dots, M_k$; $k = 1, \dots, K$ and λ_j , $j = 1, \dots, 3$ are Lagrangian multipliers. To solve the problem, an iterative method is applied. For each column j , $T_k[., j]$ is solved while keeping the other columns of T_k . α and β are also solved while keeping the others. The Karush-Kuhn-Tucker conditions are

- Stationarity: $\frac{\partial L}{\partial T_k[i, j]} = 0$, $\frac{\partial L}{\partial \alpha} = 0$, $\frac{\partial L}{\partial \beta} = 0$, $i = 1, \dots, 4$; $k = 1, \dots, K$; and $j = 1, \dots, n$.
- Primal feasibility: $T_k[i, j] \geq 0$, $g_r(T_k) < 0$, $i = 1, \dots, 4$; $j = 1, \dots, n$; $r = 1, \dots, R$; $k = 1, \dots, K$.
- Dual feasibility: $\mu_m^{(k)} \geq 0$, $\lambda_j \geq 0$, $m = 1, \dots, M_k$; $k = 1, \dots, K$; $j = 1, \dots, 3$.
- Complementary slackness: $\mu_m^{(k)} g_m(T_k) = 0$, $m = 1, \dots, M_k$; $k = 1, \dots, K$.

From the last three conditions, we have $\mu_m^{(k)} = 0$, $m = 1, \dots, M_k$; $k = 1, \dots, K$. Therefore, the stationarity condition can be derived as follows

$$\begin{aligned} \frac{\partial L}{\partial T_k[., j]} &= \frac{\partial \sum_{l=1}^N (y_l - \alpha R(X_l) \beta)^2}{\partial T_k[., j]} + 2\lambda_2 \frac{\partial \sum_{\substack{p \in N_1 \\ q \in N_2}} \alpha(R(X_q) - R(X_p))\beta}{\partial T_k[., j]} \\ &\quad + \lambda_3 \left(\frac{\partial \sum_{k=1}^K (\sum_{p,q \in N_1} d^2(x_p^{(k)}, x_q^{(k)}) + \sum_{p,q \in N_2} d^2(x_p^{(k)}, x_q^{(k)}))}{\partial T_k[., j]} \right. \\ &\quad \left. - \frac{\partial \sum_{\substack{p \in N_1 \\ q \in N_2}} d^2(x_p^{(k)}, x_q^{(k)})}{\partial T_k[., j]} \right) \\ &= -2\alpha_k \beta_j \left(\sum_{l=1}^N (y_l - \alpha R(X_l) \beta) X_l^T[j, .] + \lambda_2 \sum_{\substack{p \in N_1 \\ q \in N_2}} (X_p[j, .] - X_q[j, .])^T \right) \\ &\quad + 2\lambda_3 \sum_{p,q \in N_1} ((X_p[j, .], T_k[., j]) - (X_q[j, .], T_k[., j])) (X_p[j, .] - X_q[j, .])^T \\ &\quad + 2\lambda_3 \sum_{p,q \in N_2} ((X_p[j, .], T_k[., j]) - (X_q[j, .], T_k[., j])) (X_p[j, .] - X_q[j, .])^T \\ &\quad - 2\lambda_3 \sum_{\substack{p \in N_1 \\ q \in N_2}} ((X_p[j, .], T_k[., j]) - (X_q[j, .], T_k[., j])) (X_p[j, .] - X_q[j, .])^T = 0 \end{aligned}$$

Set $Z_{p,q} = (X_p - X_q)$ and set $\alpha(R(X_l))_{kj}\beta = \alpha R(X_l)\beta - \alpha_k\beta_j X_l[j, \cdot] T_k[\cdot, j]$. Therefore, the above formulation is derived as follows

$$\begin{aligned} \frac{\partial L}{\partial T_k[\cdot, j]} &= -2\alpha_k\beta_j \left(\sum_{l=1}^N (y_l - \alpha(R(X_l))_{kj}\beta) X_l^T[j, \cdot] \right. \\ &\quad \left. + \lambda_2 \sum_{\substack{p \in N_1 \\ q \in N_2}} Z_{p,q}[j, \cdot]^T \right) \\ &\quad + 2 \left(\lambda_3 \left(\sum_{p,q \in N_1} Z_{p,q}^T[j, \cdot] \otimes Z_{p,q}[j, \cdot] \right. \right. \\ &\quad \left. \left. + \sum_{p,q \in N_2} Z_{p,q}^T[j, \cdot] \otimes Z_{p,q}[j, \cdot] \right. \right. \\ &\quad \left. \left. - \sum_{\substack{p \in N_1 \\ q \in N_2}} Z_{p,q}^T[j, \cdot] \otimes Z_{p,q}[j, \cdot] \right) \right. \\ &\quad \left. + \alpha_k^2\beta_j^2 \sum_{l=1}^N X_l^T[j, \cdot] \otimes X_l^T[j, \cdot] \right) T_k[\cdot, j] \\ &= 0 \end{aligned}$$

We define the following equations

$$\begin{aligned} S(k, j) &= \lambda_3 \left(\sum_{p,q \in N_1} Z_{p,q}^T[j, \cdot] \otimes Z_{p,q}[j, \cdot] \right. \\ &\quad \left. + \sum_{p,q \in N_2} Z_{p,q}^T[j, \cdot] \otimes Z_{p,q}[j, \cdot] \right. \\ &\quad \left. - \sum_{\substack{p \in N_1 \\ q \in N_2}} Z_{p,q}^T[j, \cdot] \otimes Z_{p,q}[j, \cdot] \right) \\ &\quad + \alpha_k^2\beta_j^2 \sum_{l=1}^N X_l^T[j, \cdot] \otimes X_l^T[j, \cdot] \end{aligned} \quad (11)$$

$$\begin{aligned} B(k, j) &= \alpha_k\beta_j \left(\sum_{l=1}^N (y_l - \alpha(R(X_l))_{kj}\beta) X_l^T[j, \cdot] \right. \\ &\quad \left. + \lambda_2 \sum_{\substack{p \in N_1 \\ q \in N_2}} Z_{p,q}[j, \cdot]^T \right) \end{aligned} \quad (12)$$

Substitute equations (11) and (12) to $\frac{\partial L}{\partial T_k[\cdot, j]}$, we have

$$T_k[\cdot, j] = S(k, j)^{-1} B(k, j) \quad (13)$$

$$\begin{aligned} \frac{\partial L}{\partial \alpha} &= -2 \sum_{l=1}^N (y_l - \alpha R(X_l)\beta) (R(X_l)\beta)^T \\ &\quad + 2\lambda_1 \| \beta \|_2^2 \alpha + 2\lambda_2 \left(\sum_{\substack{p \in N_1 \\ q \in N_2}} (R(X_q) - R(X_p))\beta \right)^T \\ &= \sum_{l=1}^N \alpha (R(X_l)\beta) (R(X_l)\beta)^T - \sum_{l=1}^N y_l (R(X_l)\beta)^T \\ &\quad + \lambda_1 \| \beta \|_2^2 \alpha \\ &\quad - \lambda_2 \beta^T \left(\sum_{\substack{p \in N_1 \\ q \in N_2}} (R(X_p) - R(X_q)) \right)^T = 0 \\ \alpha &= \left(\sum_{l=1}^N y_l (R(X_l)\beta)^T + \lambda_2 \beta^T \left(\sum_{\substack{p \in N_1 \\ q \in N_2}} (R(X_p) - R(X_q)) \right)^T \right) \\ &\quad \times \left(\sum_{l=1}^N (R(X_l)\beta) (R(X_l)\beta)^T + \lambda_1 \| \beta \|_2^2 I \right)^{-1} \end{aligned} \quad (14)$$

$$\begin{aligned} \frac{\partial L}{\partial \beta} &= -2 \sum_{l=1}^N (y_l - \alpha R(X_l)\beta) (\alpha R(X_l))^T + 2\lambda_1 \| \alpha \|_2^2 \beta \\ &\quad + 2\lambda_2 \left(\sum_{\substack{p \in N_1 \\ q \in N_2}} \alpha (R(X_q) - R(X_p)) \right)^T \\ &= \sum_{l=1}^N \alpha R(X_l)\beta (\alpha R(X_l))^T - \sum_{l=1}^N y_l (\alpha R(X_l))^T \\ &\quad + \lambda_1 \| \alpha \|_2^2 \beta - \lambda_2 \left(\alpha \sum_{\substack{p \in N_1 \\ q \in N_2}} (R(X_p) - R(X_q)) \right)^T \\ &= \sum_{l=1}^N \left((\alpha R(X_l))^T \otimes (\alpha R(X_l)) \right) \beta - \sum_{l=1}^N y_l (\alpha R(X_l))^T \\ &\quad + \lambda_1 \| \alpha \|_2^2 \beta \\ &\quad - \lambda_2 \left(\alpha \sum_{\substack{p \in N_1 \\ q \in N_2}} (R(X_p) - R(X_q)) \right)^T = 0 \\ \beta &= \left(\sum_{l=1}^N \left((\alpha R(X_l))^T \otimes (\alpha R(X_l)) \right) + \lambda_1 \| \alpha \|_2^2 I \right)^{-1} \\ &\quad \times \left(\sum_{l=1}^N y_l (\alpha R(X_l))^T + \lambda_2 \left(\alpha \sum_{\substack{p \in N_1 \\ q \in N_2}} (R(X_p) - R(X_q)) \right)^T \right) \end{aligned} \quad (15)$$

The learning phase of the proposed bilinear tensor regression model is summarized in Algorithm 1. In this algorithm, transformation matrices T_k , $k = 1, \dots, K$, coefficient vectors α and β are learned together. In particular, siRNA sequences are first represented as encoding matrices. The transformation matrices T_k are initialized following trick inequality constraints generated by siRNA design rule k th. Vectors α and β are also initialized. To learn transformation matrices T_k , elements in each column of these matrices are calculated by equation (13). If they satisfy the trick inequality constraints, that column will be updated to the next solution. To learn coefficients of the proposed model, vectors α and β are updated by equations (14) and (15). The transformation matrices, vectors α and β are updated until meeting the convergence criteria, where t_{Max} denotes the maximum iterative step to update α and β , and ϵ , ϵ_1 and ϵ_2 are thresholds for the transformation matrices, vectors α and β , respectively.

Algorithm 1 Tensor Regression Learning

Input: A data set $L = \{(s_l, y_l)\}_1^N$ where s_l are siRNA sequences and y_l are their labels, a set DR of K design rules, the length n of siRNA sequences. A data set $S = \{(s_i, y_i)\}_1^N$ where s_i are scored siRNA sequences and $y_i \in \mathbb{R}$

Output: K transformation matrices T_1, T_2, \dots, T_K . Coefficient vectors α and β .

Encoding siRNA sequences in S and L .

for $rule_k$ in DR **do**

– Form the set of constraints C_k based on $rule_k$

– Initialize the transformation matrix T_k satisfying C_k .

end for

– Initialize α and β randomly.

$t = 0$ { Iterative step}

repeat

$t \leftarrow t + 1$

for $k = 1$ to K **do**

for $j = 1$ to n **do**

$v = S(k, j)^{-1}B(k, j)$ { Using equation (13)}

if (v satisfies the constraints at the position j in C_k) **then**

$T_k^{(t)}[:, j] \leftarrow v$

end if

end for

end for

Compute $\alpha^{(t)}$ using equation (14)

Compute $\beta^{(t)}$ using equation (15)

until ($(\frac{\|T_k^{(t)} - T_k^{(t-1)}\|_{Fro}}{\|T_k^{(t-1)}\|_{Fro}} \leq \epsilon)$ and $(\frac{\|\alpha^{(t)} - \alpha^{(t-1)}\|_2}{\|\alpha^{(t-1)}\|_2} \leq \epsilon_1)$ and $(\frac{\|\beta^{(t)} - \beta^{(t-1)}\|_2}{\|\beta^{(t-1)}\|_2} \leq \epsilon_2))$ or $(t > t_{Max})$

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

BTN designed, developed and implemented the method and wrote the manuscript. HTB carried out the verification and evaluation of the method and edited the manuscript. TK conceived the research problem and provided insight on biological interpretation. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Dr. Le Si Vinh for stimulating discussion, Dr. Phuong Nguyen for critical review of the manuscript.

Funding

This work was supported by JSPSs project "Computational Methods for Discovering Molecular Mechanisms of Hepatitis Pathology and Therapy", JAIST's project "Data Analytics", Vietnam National Foundation for Science and Technology (102.01–2013.04) and 322 project of Ministry of Education and Training, Vietnam.

Author details

¹School of Knowledge Science, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, Ishikawa, Japan. ²University of Engineering and Technology, Vietnam National University Hanoi, 144 Xuan Thuy, Cau Giay, Hanoi, Vietnam. ³John von Neumann Institute, Vietnam National University Ho Chi Minh City, Quarter 6, Linh Trung Ward, Thu Duc District, Ho Chi Minh, Vietnam. ⁴Graduate School of Medicine, Chiba University, 1-8-1 Inohahan, Chuo-ku, Chiba, Japan.

Received: 21 August 2014 Accepted: 10 February 2015

Published online: 13 March 2015

References

- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Klaus W, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature*. 2001;411:494–8.
- Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. *Nature*. 2004;433:71–8.
- Hutvagner G, McLachlan J, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA interference enzyme Dicer in small temporal RNA maturation. *Science*. 2001;293:834–8.
- Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. *Nature*. 2004;431:303–15.
- Sudarsana LR, Sarojamma V, Ramakrishna V. Future of RNAi in medicine: a review. *World J Med Sci*. 2007;2:1–14.
- Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. *Genes Dev*. 1999;13:3191–7.
- Vert JP, Foveau N, Lajaunie C, Vandenbrouck Y. An accurate and interpretable model for siRNA efficacy prediction. *BMC Bioinf*. 2006;7:520.
- Ui-Tei K. Optimal choice of functional and off-target effect-reduced siRNAs for RNAi therapeutics. *Front Genet*. 2013;4:107.
- Angart P, Vocelle D, Chan C, Walton SP. Design of siRNA therapeutics from the molecular scale. *Pharmaceuticals*. 2013;6:440–68.
- Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. *Yale J Biol Med*. 2012;85:187–200.
- Mutisya D, Selvam C, Lunstad BD, Pallan PS, Haas A, Leake D, et al. Amides are excellent mimics of phosphate internucleoside linkages and are well tolerated in short interfering RNAs. *Nucleic Acids Res*. 2014;42(10):6542–51.
- Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. *Gene*. 2014;538(2):217–27.
- Schramm G, Ramey R. siRNA design including secondary structure target site prediction. *Nat Med*. 2005;2(8):1–2. doi:10.1038/nmeth780. (Application Notes).
- Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. *Nature*. 2004;431:371–8.
- Ichihara M, Murakumo Y, Masuda A, Matsuura T, Asai N, Jijiwa M, et al. Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. *Nucleic Acids Res*. 2007;e123:35.

16. Mysara M, Elhefnawi M, Garibaldi JM. MysiRNA: improving siRNA efficacy prediction using a machine-learning model combining multi-tools and whole stacking energy. *J Biomed Inform.* 2012;45:528–34.
17. Sciabola S, Cao Q, Orozco M, Faustino I, Stanton RV. Improved nucleic acid descriptors for siRNA efficacy prediction. *Nucl Acids Res.* 2013;41:1383–94.
18. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev.* 2001;15:188–200.
19. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. *Nat Biotechnol.* 2003;21:1457–65.
20. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. *Biochem Biophys Res Commun.* 2004;316:1050–8.
21. Jagla B, Aulner N, Kelly PD, Song D, Volchuk A, Zatorski A, et al. Sequence characteristics of functional siRNAs. *RNA.* 2005;11:864–72.
22. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. *Nat Biotechnol.* 2004;22:326–30.
23. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. *Nucleic Acids Res.* 2004;32:936–48.
24. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. *Cell.* 2003;115(2):199–208.
25. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. *Cell.* 2003;115(2):209–16.
26. Gong W, Ren Y, Xu Q, Wang Y, Lin D, Zhou H, et al. Integrated siRNA design based on surveying of features associated with high RNAi effectiveness. *BMC Bioinf.* 2006;7:516.
27. Ren Y, Gong W, Xu Q, Zheng X, Lin D, Wang Y, et al. siRecords: an extensive database of mammalian siRNAs with efficacy ratings. *Bioinformatics.* 2006;22:1027–8.
28. Shabalina SA, Spiridonov AN, Ogurtsov AY. Computational models with thermodynamic and composition features improve siRNA design. *BMC Bioinf.* 2006;7:65.
29. Huesken D, Lange J, Mickanin C, Weiler J, Asselbergs F, Warner J, et al. Design of a Genome-Wide siRNA Library Using an Artificial Neural Network. *Nat Biotechnol.* 2005;23:955–1001.
30. Matveeva O, Nechipurenko Y, Rossi L, Moore B, Ogurtsov AY, Atkins JF, et al. Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. *Access.* 2007;35:1–10.
31. Qiu S, Lane T. A framework for multiple kernel support vector regression and its applications to siRNA efficacy prediction. *IEEE/ACM Trans Comput Biol Bioinform.* 2009;6:190–9.
32. Chang PC, Pan WJ, Chen CW, Chen YT, Chu YW. A design engine of siRNA that integrates SVMs prediction and feature filters. *Biocatal Agric Biotechnol.* 2012;1:129–34.
33. Klingelhofer JW, Moutsianas L, Holmes CC. Approximate Bayesian feature selection on a large meta-dataset offers novel insights on factors that effect siRNA potency. *Bioinformatics.* 2009;25:1594–601.
34. Qi L, Han Z, Ruixin Z, Ying X, Zhiwei C. Reconsideration of in silico siRNA design from a perspective of heterogeneous data integration: problems and solutions. *Brief Bioinform.* 2014;15:292–305.
35. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. *J Biol Chem.* 2003;278:7108–18.
36. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. *Antisense Nucleic Acid Drug Dev.* 2003;13:83–105.
37. Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, et al. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. *Nucleic Acids Res.* 2004;32:893–901.
38. Takasaki S. Methods for selecting effective siRNA target sequences using a variety of statistical and analytical techniques. *Methods Mol Biol.* 2013;942:17–55.
39. Saetrom P. Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming. *Bioinformatics.* 2004;20(17):3055–63.
40. Takasaki S, Kotani S, Konagaya A. An effective method for selecting siRNA target sequences in mammalian cells. *Cell Cycle.* 2004;3(6):790–5.
41. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. *Cell.* 2003;115:209–16.
42. Chalk A, Wahlestedt C, Sonhammer E. Improved and automated prediction of effective siRNA. *Biochem Biophys Res Commun.* 2004;319(1):264–74.
43. Luo K, Chang D. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. *Biochem Biophys Res Commun.* 2004;318(1):303–10.
44. Katoh T, Suzuki T. Specific residues at every third position of siRNA shape its efficient RNAi activity. *Nucleic Acids Res.* 2007;e27:35.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

